Eisai wins reimbursement for Zebinix in France, just Italy to go
This article was originally published in Scrip
Eisai's epilepsy drug, Zebinix (eslicarbazepine acetate) has won reimbursement in France as an adjunct therapy for adults with partial onset seizures. This means that the firm has only to seek reimbursement in Italy, where a new submission is underway to try and secure a better price, Eisai told Scrip.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.